Esteve Targets Expansions in Spain and China
Esteve is investing EUR 180 million ($199 million) to expand is small-molecule active pharmaceutical ingredient (API) manufacturing capacity in Europe and China. Daniel Calvo, Head of Business Account Management, Esteve, detailed the company’s expansion plans at the DCAT Member Company Announcement Forum at DCAT Week.
A key investment is at the company’s facility in Celrà, Spain, where it is expanding its capacity to manufacture high-potency active pharmaceutical ingredients (HPAPIs). The company is investing EUR 100 million ($111 million) in infrastructure and technology for the first phase for a new manufacturing facility, which will cover workshops and different warehousing facilities and enlarge reaction volume to 450 m3, a 45% increase in current production capacity. The expansion is expected to be operational in 2026.
In total, in Spain, Esteve has a chemical R&D center in Barcelona and three production plants in Catalonia located in Celrà (Gironès), Banyeres del Penedès (Baix Penedès), and Lliçà de Vall (Vallès Oriental). Outside of Spain, the company has manufacturing centers in Mexico (Jiutepec) and China (Shaoxing).
In Shaoxing, China, the company is investing EUR 80 million ($89 million) for a new API manufacturing facility. The facility will include three workshops with 250 m3 in reaction volume with the potential for future expansion of 150 m3. Service and utility units are being built to support the whole project reaction volume of 400 m3.